Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally.
The last earnings update was 147 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sonoma Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sonoma Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sonoma Pharmaceuticals is loss making, we can't compare it's value to the US Pharmaceuticals industry average.
Sonoma Pharmaceuticals is loss making, we can't compare the value of its earnings to the US market.
Price based on expected Growth
Sonoma Pharmaceuticals's expected growth come at a high price?
Sonoma Pharmaceuticals is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Sonoma Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
Sonoma Pharmaceuticals is covered by less than 3 analysts.
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Sonoma Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 4.5%.
Growth vs Market Checks
Sonoma Pharmaceuticals's earnings growth is expected to exceed the US market average.
Sonoma Pharmaceuticals's revenue growth is expected to exceed the US market average.
Annual Growth Rates Comparison
Analysts growth expectations
High Growth Checks
Sonoma Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Sonoma Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
Unable to establish if Sonoma Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Sonoma Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Sonoma Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Sonoma Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Sonoma Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Sonoma Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 42.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Sonoma Pharmaceuticals's level of debt (2.6%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (49.8% vs 2.6% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we analyse their runway based on operating expenses, which includes recurring G&A and R&D. Analysis based on the most recent financials.
Sonoma Pharmaceuticals's cash level is insufficient to cover its current level of operating expenses for the upcoming year.
Sonoma Pharmaceuticals's cash level is insufficient to cover its operating expenses for the upcoming year, if it continues to grow at historical rates of 8.8% each year.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. James Schutz, also known as Jim, has been the Chief Executive Officer and President of Oculus Innovative Sciences, Inc. since February 4, 2013. Mr. Schutz served as Vice President of Corporate Development and General Counsel of Oculus Innovative Sciences, Inc. since August 2003 and its Corporate Secretary since June 2006. Mr. Schutz served as Chief Operating Officer of Oculus Innovative Sciences, Inc. From August 2001 to August 2003, Mr. Schutz served as Corporate Secretary and General Counsel at Jomed Inc., (formerly EndoSonic Corp.) an international medical device company. From 1999 to July 2001, he served as in-house counsel at Urban Media Communications Corporation, an Internet/telecom company based in Palo Alto, California. He has been a Director of Oculus Innovative Sciences, Inc. since May 2004. Mr. Schutz graduated from the University of California, San Diego with an B.A. in economics and obtained his law degree from the University of San Francisco School of Law.
Jim's compensation has increased whilst company is loss making.
Jim's compensation is higher than average for a company of this size and profit level.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Sonoma Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
CFO, COO & Corporate Secretary
Executive Vice President of International Operations & Sales
Director of Research & Development
Chief Strategy & Marketing Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sonoma Pharmaceuticals board of directors is about average.
Board of Directors
Lead Independent Director
Recent Insider Trading
More shares have been bought than sold by Sonoma Pharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Who Owns Most Of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)?
Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … With 5.78% ownership, SNOA insiders is an important ownership type. … This is a positive sign for potential investors as these firms play an important role in aligning company policy with shareholder returns.Next Steps: SNOA's considerably high level of institutional ownership calls for further analysis into its margin of safety.
Does Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) -32.83% Earnings Drop Reflect A Longer Term Trend?
The two benchmarks I used were Sonoma Pharmaceuticals's average earnings over the past couple of years, and its industry performance. … NasdaqCM:SNOA Income Statement Apr 24th 18 We can further evaluate Sonoma Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years. … Inspecting growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 11.92% over the past twelve months, and a less exciting 9.86% over the previous five years.
What You Must Know About Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) Financial Strength
Over the past year, SNOA has ramped up its debt from US$114.00K to US$410.00K – this includes both the current and long-term debt. … NasdaqCM:SNOA Historical Debt Apr 10th 18 Can SNOA service its debt comfortably? … SNOA is not taking on too much debt commitment, which may be constraining for future growth.
Loss-Making Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) Expected To Breakeven
See our latest analysis for Sonoma Pharmaceuticals According to the industry analysts covering SNOA, breakeven is near. … Therefore, SNOA is expected to breakeven roughly 4 years from now. … For a more comprehensive look at SNOA, take a look at SNOA’s company page on Simply Wall St.
Is It Time To Buy Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)?
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. … The stock’s ratio of 1.28x is currently trading slightly below its industry peers’ ratio of 2.59x, which means if you buy Sonoma Pharmaceuticals today, you’d be paying a relatively reasonable price for it. … And if you believe Sonoma Pharmaceuticals should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading.
Flavor Of The Month: Sonoma Pharmaceuticals And More
SNOA ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. … USNA ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. … Moreover, the 27.18% growth in operating cash flows shows that a decent part of earnings is driven by robust cash generation from operational activities, not one-off or non-core activities.
What You Must Know About Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) Financial Strength
How does SNOA’s operating cash flow stack up against its debt? … However, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … This indicates room for improvement as its cash flow covers less than a quarter of its borrowings, which means its operating efficiency could be better.
Is It The Right Time To Buy Sonoma Pharmaceuticals Inc (SNOA)?
Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at SNOA future expectations. … With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. … Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy SNOA.
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. Its products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis. The company’s Microcyn medical devices are used for cleaning, debridement, lubricating, moistening, and dressing of acute and chronic wounds in tissue care management. It also operates a microbiology contract testing laboratory that offers consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. Sonoma Pharmaceuticals, Inc. sells its products directly to end users, as well as to distributors; and through in-house sales force and call center to hospitals, physicians, nurses, and other healthcare practitioners. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
This website contains factual information only (RG244B) and not general or personal advice. It does not take into account your investment objectives, financial situation or needs. You should seek independent financial and legal advice to consider if an investment is appropriate for your personal circumstances.